October 10, 2011
Chugai Pharmaceutical announced on September 26 that the anti-malignant tumor agent Avastin for IV Infusion 100 mg/4 mL and 400 mg/16 mL (recombinant bevacizumab) received an additional indication on the same day for inoperable or recurrent breast cancer. The company...read more